S&P Futures
4,231.00 +21.25 (+0.50%) Dow Futures
33,458.00 +154.00 (+0.46%) Nasdaq Futures
13,381.00 +69.75 (+0.52%) Russell 2000 Futures
1,988.80 +12.50 (+0.63%) Crude Oil
94.11 -0.23 (-0.24%) Gold
1,801.90 -5.30 (-0.29%)
Agile Therapeutics, Inc. (AGRX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.6345 |
| Open | 0.6435 |
| Bid | 0.0000 x 41800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 0.6300 - 0.6700 |
| 52 Week Range | 0.4850 - 50.4000 |
| Volume | |
| Avg. Volume | 10,961,943 |
| Market Cap | 20.213M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -26.1610 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGRX
Related Research
- Agile Therapeutics, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.RatingFair ValueEconomic Moatlast yearMorningstar
- Motley Fool
Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook and financing prospects for the future; our outlook for the second half of 2022; management's expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla; our business strategy; our partnership with Afaxys and its ability to promote growth; our product supply agreement with Nurx and its ability to educate patients about Twirla; our connected TV campaign and its ability to promote growth; and our assessment of the combined hormonal contraceptive market in general, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
- GlobeNewswire
Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla® Product Supply Agreement with Nurx Management to Host Conference Call Today, Thursday, August 11, 2022 at 4:30 p.m. ET PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended June 30, 2022 and pr
- GlobeNewswire
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. DateThursday, August 11, 2022Time4:30
